ESMO-ESTRO consensus statements on the safety of combining radiotherapy with EGFR, ALK, or BRAF/MEK inhibitors

Key Points

• The aim is to assess the safety of combining radiotherapy with specific targeted agents including EGFR, ALK, and BRAF/MEK inhibitors.
• Consensus statements developed by ESMO and ESTRO experts
• Evaluation of scenarios for drug interruptions or dosage reductions
• Assessment of radiotherapy adaptation strategies.
• Increased toxicity is likely when combining treatments
• Recommendations for drug interruption or reduction to manage risks
• Advocacy for significant adjustments in radiotherapy protocols.

Abstract